https://orcid.org/0000-0002-5377-0901
Abstract
The dexamethasone (DEX)-sparing strategy, which limits administration of DEX to day one, is reportedly non-inferior to conventional antiemetic regimens comprising multiple-day DEX. However, the usefulness of the DEX-sparing strategy in triplet antiemetic prophylaxis (neurokinin-1 receptor antagonist [NK1RA] + serotonin receptor antagonist [5HT3RA] + DEX) for carboplatin and moderate emetogenic chemotherapy (MEC) has not been clarified.
We systematically reviewed randomized controlled trials that examined the efficacy of antiemetics for preventing chemotherapy-induced nausea and vomiting associated with carboplatin and MEC. We conducted a network meta-analysis to compare the antiemesis efficacy of three-day DEX with NK1RA (3-DEX + NK1RA) and one-day DEX with NK1RA (1-DEX + NK1RA). The primary outcome was complete response during the delayed phase (CR-DP). The secondary outcome was no nausea during the delayed phase (NN-DP).
Seventeen trials involving 4534 patients were included. The proportion who experienced CR-DP was 82.5% (95% credible interval [CI], 73.9-88.6) and 73.5% (95% CI, 62.8-80.9) among those who received 3-DEX + NK1RA and 1-DEX + NK1RA, respectively. There was no significant difference between the two regimens. However, 3-DEX + NK1RA tended to be superior to 1-DEX + NK1RA, with an absolute risk difference of 9.0% (95% CI, −2.3 to 21.1) in CR-DP and 24.7% (95% CI: −14.9 to 54.6) in NN-DP. 3-DEX + NK1RA also tended to be superior to 1-DEX + NK1RA in patients who received carboplatin-based chemotherapy, for whom the absolute risk difference was 12.3% (95% CI, −3.2 to 30.7).
Care is needed when administering the DEX-sparing strategy in combination with NK1RA to patients receiving carboplatin and non-carboplatin MEC.
This study demonstrated that a three-day dose of dexamethasone (DEX) with neurokinin-1 receptor antagonist (NK1RA) was nonsignificantly superior to a one-day dose of DEX with NK1RA as prophylaxis for delayed-onset nausea and vomiting. The absolute risk difference in complete response during the delayed phase was 9.0% among patients who received moderate emetogenic chemotherapy (MEC), and 12.3% among patients who received carboplatin. Therefore, we propose that the majority of patients, with the exception of patients who should receive minimal DEX, such as those intolerant to corticosteroids, should receive DEX beyond day one of treatment when receiving non-carboplatin MEC or carboplatin.
Introduction
Chemotherapy-induced nausea and vomiting (CINV) often reduces quality of life, treatment adherence, treatment efficacy, and curability in patients receiving chemotherapy. It is important to minimize the incidence of CINV to improve patients’ quality of life and ensure they continue chemotherapy.
Although dexamethasone (DEX) is effective for suppressing CINV, short-term steroid use as antiemetic prophylaxis for chemotherapy can cause steroid-induced adverse events such as elevated blood glucose levels,1 reduced bone mineral density,2 and other symptoms.3 Several studies and meta-analyses have shown that, as an antiemetic prophylaxis, the DEX-sparing strategy, which involves limiting administration of DEX to day one, in combination with palonosetron is non-inferior to multiple-day DEX.4-10 In terms of high emetogenic chemotherapy (HEC), a randomized phase III trial showed a one-day dose of DEX is non-inferior to a three-day dose of DEX in combination with neurokinin-1 receptor antagonist (NK1RA) and palonosetron in patients receiving anthracycline plus cyclophosphamide therapy. On the other hand, a one-day dose of DEX was indicated to be insufficient to control CINV in patients receiving cisplatin-containing regimen.11 Thus, global guidelines recommend continuous administration of DEX in the delayed phase (DP) for patients receiving cisplatin-containing chemotherapy.12-15
Recent guidelines classify carboplatin from a moderate emetogenic chemotherapy (MEC) to HEC,12-15 and recommend that patients receiving carboplatin area under the curve ≥ 4 mg/mL/min be offered triplet antiemetic prophylaxis, which combines a NK1RA with a 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and DEX.12-15 For patients receiving carboplatin, American Society of Clinical Oncology and Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) guidelines recommend combining a one-day DEX dose with NK1RA and 5HT3RA.14,15 However, the recently updated National Comprehensive Cancer Network (NCCN) guideline recommends the DEX-sparing strategy be limited to patients with few specific risk factors for CINV or intolerance to corticosteroids.12 A recent trial by Iihara et al. showed that CINV associated with carboplatin occurs in the DP rather than the acute phase.16 A propensity score matching retrospective cohort study (N = 56) using data from a prospective observational study in clinical practice showed that a three-day dose of DEX was significantly superior to a one-day dose of DEX in triplet antiemetic prophylaxis for preventing nausea in patients receiving carboplatin.17
However, no randomized controlled trial (RCT) to date has examined the usefulness of combining DEX-sparing strategy with NK1RA in patients receiving carboplatin. For patients receiving non-carboplatin MEC, global guidelines recommend adding NK1RA to DEX and 5HT3RA as one antiemetic prophylaxis option,12,13 while the usefulness of combining the DEX-sparing strategy with NK1RA has not been established for these patients either. It is necessary to clarify the role of DEX in preventing delayed-onset CINV in triple antiemetic prophylaxis for patients receiving carboplatin and non-carboplatin MEC.
Therefore, we conducted a network meta-analysis (NMA) to compare one-day and three-day DEX in combination with NK1RA for preventing CINV associated with carboplatin and non-carboplatin MEC.
Patients and Methods
Objectives
The present study aimed to compare one-day versus three-day DEX in combination with NK1RA and 5HT3RA for preventing CINV associated with carboplatin and non-carboplatin MEC described in the most recent NCCN guideline.12 The present NMA was prospectively registered (PROSPERO registration number: CRD42021256346) and was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Inclusion and Exclusion Criteria
Randomized (phase II or III) clinical trials were included if they were published in English. Trials of interest were those that compared the efficacy of globally available antiemetics in adult patients with cancer receiving carboplatin or non-carboplatin MEC. Trials that compared two of the following antiemetic strategies were included: (1) three-day DEX with NK1RA (3-DEX + NK1RA), (2) one-day DEX with NK1RA (1-DEX + NK1RA), (3) three-day DEX (3-DEX), and (4) one-day DEX (1-DEX). Studies that used drugs other than DEX, 5HT3RA, and NK1RA for antiemetic prophylaxis, such as olanzapine or metoclopramide, were excluded.
Outcome Measures
The primary outcome was complete response (CR; no emesis and no rescue medication) during the DP (24-120 h after chemotherapy initiation). The secondary outcome was no nausea during the DP (NN-DP). For the primary outcome, subgroup analysis was performed in patients who received carboplatin-based chemotherapy and those who received a three-day dose of first-generation 5HT3RA or single dose of palonosetron (long 5HT3RA). All outcome variables were extracted in the first planned chemotherapy cycle.
Study Selection and Data Extraction
We systematically searched for eligible RCTs published through May 15, 2021 using PubMed and Ovid-MEDLINE. We used a combination of the terms “chemotherapy-induced nausea and vomiting,” “moderately emetogenic chemotherapy,” “steroid-sparing,” “neurokinin-1 receptor antagonists,” “fosaprepitant,” “ezlopitant,” “netupitant,” “rolapitant,” and “aprepitant” to find relevant articles (see Supplementary Table S1 for details). An additional search through the reference lists of relevant reviews and meta-analyses was also conducted. Two reviewers (D.W. and H.I.) independently assessed the abstracts of all relevant studies to confirm their eligibility and extracted details from the included studies, including the study design, study population characteristics, inclusion criteria, outcome measures, chemotherapy regimen, and details of the antiemetic regimen. Decisions made by each of the two reviewers were compared, and any disagreement was resolved through consensus between the two reviewers.
Risk of Bias Assessment
Two reviewers (D.W. and H.I.) independently assessed the risk of bias due to the randomization process, deviations from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results, and other biases of the included studies (Supplementary Table S2) using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) by The Cochrane Collaboration (http://www.cochrane.de). Any disagreement was resolved through consensus between the two reviewers.
Statistical Analysis
An arm-based NMA using Bayesian methods was conducted to compare multiple antiemetic strategies. NMA enables the direct comparison of treatments in individual trials and indirect comparison between trials simultaneously.18 In particular, an arm-based approach can be used estimate the population-averaged treatment-specific event rate. The proportions of CR-DP and NN-DP in each antiemetic strategy were aggregated using the nma.ab.bin function in the R package, pcnetmeta.19 The statistical heterogeneity in each treatment arm was evaluated using the I2 statistic with the metaprop function in the R package, meta. An I2 > 50% indicated statistically significant heterogeneity (Supplementary Table S3). A random effects model was used to consider heterogeneity, and the correlations between treatments were assumed to be different. Final estimation routines used 3 chains of 10 000 burn-in iterations, with 50 000 estimation iterations without thinning, resulting in 120 000 iterations for analysis. The results of NMA were estimated using posterior median with corresponding 95% credible intervals (CIs), which can be interpreted in the same manner as 95% confidence intervals. Statistical significance was indicated when the lower limit of one 95% CI exceeded the upper limit of the other 95% CI.
Results
Eligible Studies and Characteristics
Figure 1 shows a flow diagram of the study selection process. Among the 745 published papers on CINV identified by searching databases, we focused on 24 potentially relevant randomized control trials. We further excluded several trials because they did not use corticosteroids as an antiemetic prophylaxis (n = 2)20,21; used casopitant, which is not approved by the U.S. Food and Drug Administration, as an antiemetic prophylaxis (n = 1)22; used a crossover design and did not report the outcomes of the first chemotherapy (n = 1)23; examined chemotherapy including multiple day administration of MEC (n = 2)24,25; or did not examine the endpoints of interest for this study (n = 1).26 Ultimately, 17 trials were included in our analyses.5,27-42 One article43 was a post-hoc analysis of another eligible study38; the former was used for subgroup analyses.
PRISMA diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Table 1 summarizes the characteristics of all included trials. Eight trials compared 3-DEX + NK1RA and 3-DEX,27,30,31,33,34,36,39,40 five trials compared 1-DEX + NK1RA and 1-DEX,32,37,38,41,42 and four trials compared 3-DEX and 1-DEX,5,28,29,35 while no trials directly compared 3-DEX + NK1RA with 1-DEX + NK1RA (Supplementary Figure S1). Of the 4534 patients included this NMA, 11.0% (n = 499) received 3-DEX + NK1RA, 31.7% (n = 1438) received 1-DEX + NK1RA, 18.5% (n = 839) received 3-DEX, and 38.8% (n = 1758) received 1-DEX. The proportion of patients who received carboplatin-based chemotherapy was 49.6% (n = 2250). Among those administered NK1RAs, 57.5% (n = 1113) received aprepitant, 25.9% (n = 502) received fos-aprepitant, and 16.6% (n = 322) received rolapitant. Among those administered 5HT3RAs, 42.4% (n = 1923) received a first-generation 5HT3RA on day one only, 35.4% (n = 1603) received a first-generation 5HT3RA from day one to three, and 19.7% (n = 895) received palonosetron. The type of 5HT3RA administered to the remaining 2.5% (n = 113) was unclear.
Study characteristics and patient demographics of studies included in the network meta-analysis
| Study name | Major chemotherapy regimen | NK1RA | 5HT3RA | DEX | N (male/female) | Carboplatin-based regimen (%) | CR-DP | NN-DP |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
| Study name | Major chemotherapy regimen | NK1RA | 5HT3RA | DEX | N (male/female) | Carboplatin-based regimen (%) | CR-DP | NN-DP |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
Data could not be extracted from among the other chemotherapy regimens.
Abbreviations: 5HT3RA, serotonin receptor antagonist; APR, aprepitant; CR-DP, complete response during delayed phase; DEX, dexamethasone; FAPR, fos-aprepitant; GRN, granisetron; NA, not available; NK1RA, neurokinin-1 receptor antagonist; NN-DP, no nausea during delayed phase; OND, ondansetron; Palo, palonosetron; ROL, rolapitant.
Study characteristics and patient demographics of studies included in the network meta-analysis
| Study name | Major chemotherapy regimen | NK1RA | 5HT3RA | DEX | N (male/female) | Carboplatin-based regimen (%) | CR-DP | NN-DP |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
| Study name | Major chemotherapy regimen | NK1RA | 5HT3RA | DEX | N (male/female) | Carboplatin-based regimen (%) | CR-DP | NN-DP |
|---|---|---|---|---|---|---|---|---|
| Aridome_2016 | Oxaliplatin-based | APR | Any 5HT3RA | 3-day | 59 (34/25) | 0 | 47/59 | 38/59 |
| — | Any 5HT3RA | 3-day | 54 (30/24) | 0 | 43/54 | 37/54 | ||
| Celio_2011 | Carboplatin-based Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 100 | 16 (16.0) | 76/100 | NA |
| — | Palo | 1-day | 111 | 21 (18.9) | 79/111 | NA | ||
| Furukawa_2015 | Carboplatin-based | — | Palo | 3-day | 39 (0/39) | 39 (100) | 30/39 | 25/39 |
| — | Palo | 1-day | 43 (0/43) | 43 (100) | 30/43 | 26/43 | ||
| Ito_2014 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 3-day | 67 (56/11) | 67 (100) | 54/66 | 35/66 |
| — | First-generation 5HT3RA day 1 | 3-day | 67 (54/13) | 67 (100) | 46/67 | 29/67 | ||
| Kaushal_2015 | Carboplatin-based | APR | Palo | 3-day | 30 (29/1) | 30 (100) | 25/30 | 23/30 |
| — | OND day 1-3 | 3-day | 30 (23/7) | 30 (100) | 16/30 | 13/30 | ||
| Kim_2017 | Carboplatin-based Oxaliplatin-based Irinotecan-based | APR | OND day 1 | 1-day | 237 (129/108) | 156 (65.8) | 176/237 | NA |
| — | OND day 1-3 | 1-day | 243 (134/109) | 156 (64.2) | 173/243 | NA | ||
| Komatsu_2015 | Oxaliplatin-based Irinotecan-based | — | Palo | 3-day | 154 (87/67) | 19 (12.3) | 100/154 | NA |
| — | Palo | 1-day | 151 (86/65) | 18 (11.9) | 101/151 | NA | ||
| Kusagaya_2015 | Carboplatin-based | APR | Palo | 3-day | 41 (29/12) | 41 (100) | 33/41 | NA |
| — | Palo | 3-day | 39 (28/11) | 39 (100) | 30/39 | NA | ||
| Maehara_2015 | Carboplatin-based | APR | GRA day 1 | 3-day | 11 (0/11) | 11 (100) | 11/11 | 10/11 |
| — | GRN day 1 | 3-day | 12 (0/12) | 12 (100) | 8/12 | 2/12 | ||
| Matsuura_2015 | Carboplatin-based | — | Palo | 3-day | 53 (0/53) | 53 (100) | 36/53 | NA |
| — | Palo | 1-day | 56 (0/56) | 56 (100) | 34/56 | NA | ||
| Nishimura_2015 | Oxaliplatin-based | APR | 5HT3RA day 1 | 3-day | 207 (126/81) | 0 | 159/187 | 124/187 |
| — | 5HT3RA day 1 | 3-day | 206 (126/80) | 0 | 138/183 | 113/183 | ||
| Rapoport_2010 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | APR | OND day 1 | 1-day | 226 | NAa | 172/226 | NA |
| — | OND day 1-3 | 1-day | 203 | NAa | 140/203 | NA | ||
| Schwartzberg_2015 | Carboplatin-based Irinotecan-based Oxaliplatin-based Other non-AC MEC | ROL | GRN day 1-3 | 1-day | 322 | 191 (59.3) | 245/322 | NA |
| — | GRN day 1-3 | 1-day | 307 | 209 (68.1) | 196/307 | NA | ||
| Sugimori_2017 | Carboplatin-based | APR | Palo | 3-day | 39 (0/39) | 39 (100) | 38/39 | 27/39 |
| — | Palo | 3-day | 39 (0/39) | 39 (100) | 32/39 | 25/39 | ||
| Tanioka_2013 | Carboplatin-based | APR | GRN day 1 | 3-day | 45 (0/45) | 44 (97.8) | 28/45 | NA |
| — | GRN day 1 | 3-day | 46 (0/46) | 45 (97.8) | 24/46 | NA | ||
| Weinstein_2016 | Carboplatin-based Oxaliplatin-based | FAPR | OND day 1 | 1-day | 502 (204/298) | 257 (51.2) | 396/502 | NA |
| — | OND day 1-3 | 1-day | 498 (205/293) | 256 (51.4) | 341/498 | NA | ||
| Yahata_2016 | Carboplatin-based | APR | First-generation 5HT3RA day 1 | 1-day | 155 (0/155) | 155 (100) | 96/151 | 61/151 |
| — | First-generation 5HT3RA day 1 | 1-day | 152 (0/152) | 152 (100) | 72/146 | 49/146 |
Data could not be extracted from among the other chemotherapy regimens.
Abbreviations: 5HT3RA, serotonin receptor antagonist; APR, aprepitant; CR-DP, complete response during delayed phase; DEX, dexamethasone; FAPR, fos-aprepitant; GRN, granisetron; NA, not available; NK1RA, neurokinin-1 receptor antagonist; NN-DP, no nausea during delayed phase; OND, ondansetron; Palo, palonosetron; ROL, rolapitant.
Proportion Experiencing CR-DP and NN-DP in Each Antiemetic Regimen
The proportion of patients who experienced CR-DP was 82.5% (95% CI, 73.9-88.6), 73.5% (95% CI, 62.8-80.9), 70.4% (95% CI: 63.3-76.3), and 65.5% (95% CI, 57.8-72.2) among those who received 3-DEX + NK1RA, 1-DEX + NK1RA, 3-DEX, and 1-DEX, respectively (Figure 2). Meanwhile, the proportion who experienced NN-DP was 67.9% (95% CI, 54.9-79.3), 42.8% (95% CI, 15.2-81.5), 51.6% (95% CI, 35.5-65.9%), and 35.4% (95% CI, 12.4-72.3) among patients who received 3-DEX + NK1RA, 1-DEX + NK1RA, 3-DEX, and 1-DEX, respectively (Figure 3).
Proportion of patients who experienced complete response during the delayed phase in each antiemetic regimen among the entire population.
Proportion of patients who experienced no nausea during the delayed phase in each antiemetic regimen among the entire population.
Among patients who received carboplatin-based chemotherapy, the proportion who experienced CR-DP was 86.9% (95% CI, 75.5-93.3), 74.4% (95% CI, 57.8-85.2), 70.5% (95% CI, 59.3-79.3), and 61.6% (95% CI, 48.7-72.8) of those who received 3-DEX + NK1RA, 1-DEX + NK1RA, 3-DEX, and 1-DEX, respectively (Figure 4). Meanwhile, among patients who received long 5HT3RA, the proportion who experienced CR-DP was 86.9% (95% CI, 71.2-94.3), 75.1% (95% CI, 44.0-91.4), 71.0% (95% CI, 60.7-79.3), and 67.4% (95% CI, 59.9-74.0) of those who received 3-DEX + NK1RA, 1-DEX + NK1RA, 3-DEX, and 1-DEX, respectively (Figure 5).
Proportion of patients who achieved complete response during the delayed phase in each antiemetic regimen among those who received a carboplatin-based regimen.
Proportion of patients who achieved complete response during the delayed phase in each antiemetic regimen among those treated with a three-day dose of first-generation 5HT3RA or single dose of palonosetron. 5HT3RA, 5-hydroxytryptamine-3 receptor antagonist.
Pairwise Comparison of 3-DEX + NK1RA and 1-DEX + NK1RA
Figure 6 shows the results of a pairwise comparison of 3-DEX + NK1RA and 1-DEX + NK1RA in CR-DP, NN-DP, and CR-DP in patients who received carboplatin-based chemotherapy and in CR-DP in patients who received long 5HT3RA. While there were no significant differences in any outcome between 3-DEX + NK1RA and 1-DEX + NK1RA, 3-DEX + NK1RA tended to be superior to 1-DEX + NK1RA. The absolute risk difference between 3-DEX + NK1RA and 1-DEX + NK1RA was 9.0% (95% CI, −2.3 to 21.1), 24.7% (95% CI, −14.9 to 54.6), 12.3% (95% CI, −3.2 to 30.7), and 11.4% (95% CI, −10.1 to 42.4) in CR-DP, NN-DP, and CR-DP in patients who received carboplatin-based chemotherapy and in CR-DP in patients who received long 5HT3RA, respectively.
Pairwise comparison of 3-DEX + NK1RA and 1-DEX + NK1RA. Absolute risk difference greater than 1 suggests that 3-DEX + NK1RA is more efficient than 1-DEX + NK1RA. 1-DEX + NK1RA, one-day dexamethasone with neurokinin-1 receptor antagonist; 3-DEX + NK1RA, three-day dexamethasone with neurokinin-1 receptor antagonist.
Discussion
We performed a systematic review and NMA to indirectly compare the antiemetic effects of 3-DEX + NK1RA and 1-DEX + NK1RA in patients receiving carboplatin and non-carboplatin MEC. Although we found no statistically significant differences, 3-DEX + NK1RA showed a tendency toward being superior to 1-DEX + NK1RA, and the absolute risk difference between 3-DEX + NK1RA and 1-DEX + NK1RA was 9.0% and 24.7% in CR-DP and NN-DP, respectively. These results suggest that continuous administration of DEX beyond day one may increase the benefits of prophylaxis for delayed-onset CINV in patients receiving carboplatin and non-carboplatin MEC.
Among patients who received carboplatin, we found that 3-DEX + NK1RA was nonsignificantly superior to 1-DEX + NK1RA in CR-DP, and that the absolute risk difference was 12.3%, which is clinically meaningful to the patient according to MASCC/ESMO.44 Tamura et al. reported that the CINV incidence and severity associated with cisplatin and MEC comprising mainly carboplatin and oxaliplatin peaked on days four to five.45 Iihara et al. reported that administration of carboplatin led to a high incidence of CINV that continued for more than seven days, with the severity peaking on days four to five with or without aprepitant.16 A propensity score matching retrospective cohort study that compared one-day versus three-day DEX with aprepitant and 5HT3RA for the prevention of CINV associated with carboplatin found that three-day DEX was significantly superior to one-day DEX for preventing nausea (82.5% vs. 44.4%). The study additionally found that the average severity of nausea was beyond “moderate” from day two in the one-day DEX group compared to day five in the three-day DEX group.17 Thus, CINV associated with carboplatin during the delayed phase may be more difficult to control than that in the acute phase, and continuous DEX dosing beyond day one may play an important role in preventing delayed nausea. These results support our findings, which suggest that three-day DEX with NK1RA and 5HT3RA may be preferable for patients receiving carboplatin-based chemotherapy, even if they are receiving triplet antiemetic prophylaxis.
We were unable to perform subgroup analysis of patients who received non-carboplatin MEC among the 3-DEX + NK1RA and 1-DEX + NK1RA groups due to insufficient data; thus, the superiority of 3-DEX + NK1RA over 1-DEX + NK1RA in non-carboplatin MEC remains unclear. However, given the benefit of 3-DEX + NK1RA over 1-DEX + NK1RA among the total population, continuous administration of DEX beyond day one may increase the benefit of prophylaxis for delayed-onset CINV in patients receiving non-carboplatin MEC. In particular, because oxaliplatin is known to induce a high incidence of delayed-onset nausea,45,46 DEX-sparing regimens should be used with caution in patients receiving oxaliplatin-based chemotherapy.
Delayed-onset nausea is an important part of CINV, and difficult to control.47-49 In this NMA, absolute risk difference between 3-DEX + NK1RA and 1-DEX + NK1RA in DP-NN was ≥20%. This result suggests extended DEX dose may play an important role to control delayed-onset nausea in triplet antiemetic prophylaxis with NK1RA. In previous phase III study, NK1RA did not significantly reduce visual analog scale for nausea compared to placebo.50 Thus the addition of olanzapine should be considered when limiting administration of DEX to day one in patients with identifiable risk factors for CINV because olanzapine is possibly more effective than NK1RA for preventing nausea.51-53
In this NMA, we classified patients who received a three-day dose of a first-generation 5HT3RA or single dose of palonosetron into the long 5HT3RA subgroup to examine them separately from patients who received single-day administration of 5HT3RA, and to set similar conditions for the effect of 5HT3RA on CINV in the delayed phase. In the long 5HT3RA group, 3-DEX + NK1RA showed a nonsignificant superior effect to 1-DEX + NK1RA, and the absolute risk difference between 3-DEX and 1-DEX in CR-DP was 11.4%. The results of a prior RCT suggested that a one-day dose of DEX in combination with palonosetron and NK1RA was an insufficient antiemetic prophylaxis for a cisplatin-containing regimen.11 In contrast, a recent study reported that the DEX-sparing strategy in combination with netupitant and palonosetron showed comparable antiemetic effects to four-day DEX in patients receiving cisplatin-based chemotherapy.54 Future studies should examine the usefulness of the DEX-sparing strategy in combination with netupitant and palonosetron for carboplatin and non-carboplatin MEC.
Cost is an important factor when selecting antiemetic measures. DEX is less expensive than other antiemetic agents such as palonosetron and NK1RAs. Given that our results suggest there may be considerable benefits to continuous DEX administration, we propose that the majority of patients, with the exception of patients who should receive minimal DEX, such as those intolerant to corticosteroids, should receive DEX beyond day one of treatment.
This NMA has several limitations. First, many of our arguments are based on indirect comparisons between 3-DEX + NK1RA and 1-DEX + NK1RA, which cannot replace the direct comparisons obtained from randomized studies. Second, we could not examine the outcome for those using non-carboplatin MEC due to insufficient data. Further randomized studies are needed to determine the benefits of the DEX-sparing regimen in triplet antiemetic prophylaxis, especially those containing carboplatin and oxaliplatin, which have been shown to benefit from the addition of NK1RA and to lead to a high incidence of delayed-onset CINV.16,45,46,55 Third, individual studies in this population are relatively small, which significantly limits statistical power and sensitivity to detect differences. Despite these limitations, our findings, which were derived from available RCT data, highlight concerns related to using the DEX-sparing strategy in combination with NK1RA for the prevention of CINV in patients receiving carboplatin and non-carboplatin MEC.
Conclusion
Our NMA showed that a three-day dose of DEX with NK1RA tended to have greater antiemetic benefit than a one-day dose of DEX with NK1RA; the absolute risk difference between a three-day and one-day dose of DEX with NK1RA was 9.0% and 24.7% in CR-DP and NN-DP, respectively. Among patients who received carboplatin-based chemotherapy, the absolute risk difference in CR-DP between a three-day and one-day dose of DEX with NK1RA was 12.3%. Therefore, care is needed when choosing the DEX-sparing strategy with NK1RA for patients receiving carboplatin and non-carboplatin MEC. The strategy may be more suitable for selected patients, such as those with few identifiable risk factors for CINV.
Acknowledgments
We appreciate the participants for their contribution to this study. We are also grateful to Takuma Ishihara from Gifu University Hospital Innovative and Clinical Research Promotion Center, Gifu University, Gifu, Japan, for providing many suggestions on statistical analysis methods.
Funding
This study was funded by a Gifu University Hospital Pharmacy Department Operation Grant.
Conflict of Interest
Akitaka Makiyama: Eli Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Daiichi Sankyo Co. Ltd (H). The other authors indicated no financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board.
Author Contributions
Conception/design: D.W., H.I., H.F. Provision of study material/patients: D.W., H.I., S.N. Collection and/or assembly of data: D.W., H.I., S.N. Data analysis and interpretation: D.W., H.I., A.S. Manuscript writing: D.W., H.I., A.S., A.M. Final approval of manuscript: All authors.
Data Availability
The data underlying this article are available in the article and in its online supplementary material.
